

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

OBTAINING OF A HEALTH FOOD CERTIFICATE BY A WHOLLY-OWNED SUBSIDIARY

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 16 April 2014, Zhuhai Essex was granted a Health Food Certificate by 國家食品藥品監督管理總局 (China Food and Drug Administration) for a period from 16 April 2014 to 15 April 2019 in respect of 貝复®舒輝膠囊 (beifu®shuhui capsules).

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 16 April 2014, 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Company Limited*) (“**Zhuhai Essex**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred to as the “**Group**”) was granted a 國產保健食品批准證書 (Certificate of Domestic Health Food) (the “**Health Food Certificate**”) by 國家食品藥品監督管理總局 (China Food and Drug Administration) for a period from 16 April 2014 to 15 April 2019 in respect of the product known as 「貝复®舒輝膠囊 (beifu®shuhui capsules)」 (“**Approved Product**”). The Approved Product is to alleviate the tiresome of eyes.

Zhuhai Essex is principally engaged in the manufacturing and selling of biopharmaceutical products. The Approved Product is the first eye-care health product developed by the Group that has been approved for manufacturing and selling in the People's Republic of China. It is expected that the Approved Product will be launched in the market in 2015.

The Group currently has two more eye-care health products under research and development. Further announcement will be made by the Company if any of such additional eye-care health products has received approval from 國家食品藥品監督管理總局 (China Food and Drug Administration).

By order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 15 May 2014

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

* denotes an English translation of a Chinese name